The Readout Loud cover image

243: George Scangos' retirement, annual Covid vaccines, an Alzheimer's drug rejection

The Readout Loud

00:00

Lilly Drug - What's the Difference?

Lilly's drug is designed to allow patients to stop taking it if they sufficiently lower amyloid levels. That was a reason given for why there weren't enough patients to get to this milestone the FDA was looking for. Of course, A-size and biogen's drug was approved on that same accelerated approval basis,. But the difference was they'd already reported out that phase three outcomes trial.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app